Evidence map›Paper›PMID 19622820›Full record

SynthesisJAMA2009

Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.

Emerging Risk Factors Collaboration, Sebhat Erqou, Stephen Kaptoge, Philip L Perry, Emanuele Di Angelantonio, Alexander Thompson, Ian R White, Santica M Marcovina, Rory Collins, Simon G Thompson and 1 more

2 registry-linked trialsOpen access · bronzeAbstract readMeta-AnalysisReview
In one paragraph

Synthesis in JAMA, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 705 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
705citing papers in PubMed, 5 pooled it
67.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04613167 naunknown statusstarted 2020, after this paper: background citation

Genetic, Biochemical and Functional Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment Options

Ran2020Enrolled70Registered outcomes3Posted comparisons0ConditionsAcute Coronary Syndrome, Genetic Polymorphisms, Inflammation, LipoproteinemiaArmsAlirocumab, Control group, Evolocumab
Open the trial in the graph
NCT04993664 nawithdrawnnot on this mapstarted 2021, after this paper: background citation

Influence of Pelacarsen on Arterial Wall Properties and Risk Factors in Patients After Myocardial Infarction With High Lp(a) Values

TypeinterventionalSponsorUniversity Medical Centre LjubljanaRan2021 to 2022Enrolled0ConditionsAcute Coronary Syndrome, Lipoproteinemia, Inflammation, Genetic PolymorphismsArmsPelacarsen (TQJ230), Placebo
3 · Its place in the literature

Who cites it

705 citing papers in PubMed, 5 syntheses or guidelines pooled it, 1,695 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Lipoprotein(a), remote ischemic conditioning, and stroke recurrence in patients with symptomatic intracranial atherosclerotic stenosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Trial
  7. Trial
  8. Trial
  9. Lipoprotein(a) and premature myocardial infarction: Mechanistic insights and implications for PCI-era residual risk.International journal of cardiology. Cardiovascular risk and prevention · 2026
    Review
  10. Article
  11. Article
  12. Lipoprotein(a): Cardiovascular Risk and Emerging Targeted Therapies.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Observational

645 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Emerging Risk Factors Collaboration
Sebhat Erqou
Stephen Kaptoge
Philip L Perry
Emanuele Di Angelantonio
Alexander Thompson
Ian R White
Santica M Marcovina
Rory Collins
Simon G Thompson
John Danesh
University of Cambridge · GB

Funding

Archiving the Charleston Heart StudyR03AG021162 · NIA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI NIETERT, PAUL J · 2002 to 2002
$73k
British Heart Foundation RG/07/008/23674British Heart Foundation RG/08/014British Heart Foundation RG/08/014/24067Medical Research Council G0100222Medical Research Council G0600705Medical Research Council G19/35Medical Research Council G8802774Medical Research Council MC_U105260558Medical Research Council MC_U105260792Medical Research Council MC_U137686851Medical Research Council MC_U137686857NIA NIH HHS R03 AG021162Wellcome Trust
6 · The paper itself

Abstract

contextCirculating concentration of lipoprotein(a) (Lp[a]), a large glycoprotein attached to a low-density lipoprotein-like particle, may be associated with risk of coronary heart disease (CHD) and stroke.

objectiveTo assess the relationship of Lp(a) concentration with risk of major vascular and nonvascular outcomes. STUDY SELECTION: Long-term prospective studies that recorded Lp(a) concentration and subsequent major vascular morbidity and/or cause-specific mortality published between January 1970 and March 2009 were identified through electronic searches of MEDLINE and other databases, manual searches of reference lists, and discussion with collaborators. DATA EXTRACTION: Individual records were provided for each of 126,634 participants in 36 prospective studies. During 1.3 million person-years of follow-up, 22,076 first-ever fatal or nonfatal vascular disease outcomes or nonvascular deaths were recorded, including 9336 CHD outcomes, 1903 ischemic strokes, 338 hemorrhagic strokes, 751 unclassified strokes, 1091 other vascular deaths, 8114 nonvascular deaths, and 242 deaths of unknown cause. Within-study regression analyses were adjusted for within-person variation and combined using meta-analysis. Analyses excluded participants with known preexisting CHD or stroke at baseline. DATA SYNTHESIS: Lipoprotein(a) concentration was weakly correlated with several conventional vascular risk factors and it was highly consistent within individuals over several years. Associations of Lp(a) with CHD risk were broadly continuous in shape. In the 24 cohort studies, the rates of CHD in the top and bottom thirds of baseline Lp(a) distributions, respectively, were 5.6 (95% confidence interval [CI], 5.4-5.9) per 1000 person-years and 4.4 (95% CI, 4.2-4.6) per 1000 person-years. The risk ratio for CHD, adjusted for age and sex only, was 1.16 (95% CI, 1.11-1.22) per 3.5-fold higher usual Lp(a) concentration (ie, per 1 SD), and it was 1.13 (95% CI, 1.09-1.18) following further adjustment for lipids and other conventional risk factors. The corresponding adjusted risk ratios were 1.10 (95% CI, 1.02-1.18) for ischemic stroke, 1.01 (95% CI, 0.98-1.05) for the aggregate of nonvascular mortality, 1.00 (95% CI, 0.97-1.04) for cancer deaths, and 1.00 (95% CI, 0.95-1.06) for nonvascular deaths other than cancer.

conclusionUnder a wide range of circumstances, there are continuous, independent, and modest associations of Lp(a) concentration with risk of CHD and stroke that appear exclusive to vascular outcomes.

Indexed as

Cause of DeathCoronary DiseaseHumansLipoprotein(a)Risk FactorsStrokeLipoprotein(a)

Identifiers

PMID19622820
PMCPMC3272390
OpenAlexW2104355263

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.